Shattuck Labs (NASDAQ:STTK – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Shattuck Labs to post earnings of ($0.38) per share and revenue of $1.00 million for the quarter.
Shattuck Labs Price Performance
Shares of Shattuck Labs stock opened at $1.22 on Tuesday. The firm has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.77. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76. The stock has a market cap of $58.24 million, a PE ratio of -0.80 and a beta of 1.70.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.67.
Insider Activity at Shattuck Labs
In other news, Director Redmile Group, Llc purchased 133,371 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were bought at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the completion of the transaction, the director now owns 5,539,724 shares in the company, valued at $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.50% of the stock is owned by company insiders.
About Shattuck Labs
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
See Also
- Five stocks we like better than Shattuck Labs
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
